Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB2198 in Moderately to Severely Active Systemic Lupus Erythematosus
NCT07491900Phase 1Recruiting
- Sponsor
- Hinge Bio, Inc.
- Start
- Mar 2026
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HB2198 in systemic lupus erythematosus (SLE) and lupus nephritis (LN), sponsored by Hinge Bio, Inc. Primary endpoints: Number of participants experiencing treatment-emergent adverse events and serious adverse events at Day 29, Maximum tolerated dose at Day 29 and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
HB2198
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07491900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07491900.